Princeton Capital Management’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

Princeton Capital Management’s Portfolio PVCT Stock Details PVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$0	Hold	10,000	–	–	﹤0.01%	87
2016 Q3	$1K	Hold	10,000	–	–	﹤0.01%	76
2016 Q2	$4K	Hold	10,000	–	–	﹤0.01%	74
2016 Q1	$4K	Hold	10,000	–	–	﹤0.01%	74
2015 Q4	$4K	Sell	10,000 -15,000	-60%	-$7.11K	﹤0.01%	74
2015 Q3	$14K	Hold	25,000	–	–	0.02%	81
2015 Q2	$14K	Hold	25,000	–	–	0.01%	87
2015 Q1	$20K	Hold	25,000	–	–	0.02%	88
2014 Q4	$20K	Hold	25,000	–	–	0.02%	84
2014 Q3	$26K	Hold	25,000	–	–	0.02%	83
2014 Q2	$22K	Buy	+25,000	New	+$30K	0.02%	87

Other funds holding PVCT

CCB

Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return

HFBOT

Home Federal Bank of Tennessee Knoxville, Tennessee $463M AUM 24.62% 1-Year Est. Return

Princeton Capital Management's PVCT Position: Q4 2016 in Review

Princeton Capital Management held its PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) position steady in Q4 2016 at 10,000 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #87.

Princeton Capital Management first reported a position in PVCT in Q2 2014 and has held it in 11 quarters since. The position peaked at $26K in Q3 2014. 8 funds tracked by Wall St. Rank hold PVCT as of Q4 2016.

Princeton Capital Management held 10,000 shares of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) worth $0 as of Q4 2016.
Princeton Capital Management left its PROVECTUS BIOPHARMACEUTICALS, INC. (DE) share count unchanged in Q4 2016.
PROVECTUS BIOPHARMACEUTICALS, INC. (DE) made up ﹤0.01% of Princeton Capital Management's portfolio in Q4 2016, its #87 holding.
Princeton Capital Management first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q2 2014 and has held it in 11 quarters since.
Princeton Capital Management's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $26K in Q3 2014.
8 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q4 2016.

Based on Princeton Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.